Compare Alcon AG (ALC) vs Ferrari NV (RACE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Ferrari NV — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Ferrari NV trades at $375.44 (market cap $67.98B). The key difference: Ferrari NV is far larger — about 2.1× Alcon AG's market cap, and Ferrari NV pays the higher dividend (1.09%). Which is the better fit depends on your goals.
| ALC | RACE | |
|---|---|---|
Market Cap | $32.69B | $67.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $517.65 |
52-Week Low | $62.02 | $314.63 |
Enterprise Value | $36.28B | $69.19B |
Dividend Yield | 0.54% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Ferrari (RACE) trades at $386.99, up 0.52% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow. Recent news highlights the company's ongoing share buyback program and strategic moves like the new V12 model and EV developments. Analyst sentiment remains positive with a $467.50 consensus target.
The outlook is favorable given Ferrari's pricing power and hybrid sales growth, but risks include EV market reception and economic sensitivity. Wall Street's strong buy consensus (72% buy ratings) supports upside potential, though high valuation multiples warrant caution amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
